FibroGen Inc (NAS:FGEN)
$ 0.58 0.001 (0.17%) Market Cap: 58.45 Mil Enterprise Value: 48.65 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 49/100

Q3 2024 FibroGen Inc Earnings Call Transcript

Nov 12, 2024 / 10:00PM GMT
Release Date Price: $0.3866 (+14.18%)
Operator

Good day and welcome to the FibroGen third-quarter 2024 earnings conference call. (Operator Instructions) Please note this event is being recorded.

I would now like to hand the call over to David Delucia, Vice President of Investor Relations. Please go ahead.

David Delucia
FibroGen Inc - Vice President, Corporate FP&A and Investor Relations

Good afternoon, everyone. Thank you for joining today to discuss our third-quarter 2024 financial and business results. I'm David Delucia, Vice President of Corporate FP&A and Investor Relations at FibroGen. Joining me on today's call are Thane Wettig, our Chief Executive Officer; Juan Graham, our Chief Financial Officer; and Chris Chung, our Senior Vice President of China Operations. Following out the pair of remarks, we will open the call to your questions. I would like to remind you that remarks made on today's call include forward-looking statements about FibroGen.

Such statements may include but are not limited to our collaborations with AstraZeneca and Astellas financial guidance. The

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot